FRIDAY, JULY 12, 2019

10:30 a.m.  Registration
11:00 a.m.  Welcome & Introductions
            Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI
            Naoko Takebe, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI

11:05 a.m.  Opening Keynote
            Tom Misteli, Ph.D., Center for Cancer Research, NCI

11:20 a.m.  Keynote Lecture—The Role of Innate Immunity in MDS Pathogenesis
            Alan List, M.D., Moffit Cancer Center

Session 1  Introduction to MDS
Moderator: Naoko Takebe, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI

12:00 p.m.  WHO MDS Classification
            Katherine Calvo, M.D., Ph.D., Clinical Center, NIH

            Overview of MDS Standard Therapy
            Catherine Lai, M.D., Lombardi Cancer Center

Session 2  From Laboratory to Clinic
Moderator: Peter Aplan, M.D., Center for Cancer Research, NCI

12:25 p.m.  Somatic and Germ Line Mutations in AML
            Paul Liu, M.D., Ph.D., National Human Genome Research Institute, NIH

            Current Status and Advances in MRD Measurement
            Christopher Hourigan, M.D., D.Phil., National Heart, Lung, and Blood Institute
            Laura Dillon Ph.D., National Heart, Lung, and Blood Institute

            Preclinical Myeloid Leukemia Models
            Peter Aplan, M.D., Center for Cancer Research, NCI

            Novel HMAs and Combinations
            Steven Grant, M.D., Virginia Commonwealth University

            CTEP AML/MDS Precision Medicine Initiative
            Rich Little, M.D., Division of Cancer Treatment and Diagnosis, NCI

1:30 p.m.  Break

U.S. Department of Health & Human Services | National Institutes of Health
Session 2  From Laboratory to Clinic (continued)
Moderator: Nirali Shah, M.D., Center for Cancer Research, NCI
2:00 p.m.  Heterogeneity in Refractory AML
Michael Gottesman, M.D., Center for Cancer Research, NCI
Targeting HMA Refractory MDS
Daniel Larson, Ph.D., Center for Cancer Research, NCI
Strategies to Enhance Effects of Cellular Immunotherapy
Jack Shern, M.D., Center for Cancer Research, NCI
NK Cell Therapy for Myeloid Leukemia
Kate Stringaris, M.D., Ph.D., National Heart, Lung and Blood Institute, NIH
Chemotherapy Induced AML in Modern Era
Lindsay Morton, Ph.D., Division of Cancer Epidemiology and Genetics, NCI

Session 3  Active Treatment Protocols
Moderator: Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI
3:00 p.m.  DCTD Phase 1 Program
Geraldine O’Sullivan, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI
Clofarabine and Bortezomib Phase 1 Study
Naoko Takebe, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI
Sabrina Khan, M.D., MPH, Center for Cancer Research, CCR
CSF1R Blockade
Rosandra Kaplan, M.D., Center for Cancer Research, NCI
MUD RIC Transplant for Hematologic Malignancy
Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI
Haplo-Identical Donor Transplant for Hematologic Malignancy
Christopher Kanakry, M.D., Center for Cancer Research, NCI
CAR-T Cells for Acute Leukemia
Nirali Shah, M.D., Center for Cancer Research, NCI

Session 4  Inherited Leukemia Protocols
Moderator: Lea Cunningham, M.D., National Human Genome Research Institute, NCI
4:20 p.m.  Allogeneic Transplant for GATA2 Mutation
Mark Parta, Ph.D., National Institute of Allergy and Infectious Diseases, NIH
RUNX1 Clinic and Transplant Protocols
Lea Cunningham, M.D., Ph.D., National Human Genome Research Institute, NCI
Other Inherited Leukemias
Lisa McReynolds, M.D., Ph.D., Division of Cancer Epidemiology and Genetics, NCI
5:00 p.m.  Wrap-up and Adjourn